

DEPARTMENT OF
VETERANS AFFAIRS

Memorandum

Date: **AUG 01 2019**

From: Director, Biomedical Laboratory Research & Development Service (10X2B)

Subj: Research Career Scientist Award #1IK6BX004835

To: Director, San Francisco VA Health Care System, San Francisco, CA (662)

1. The Research Career Scientist Evaluation Committee has recommended Wenhan Chang, Ph.D. for a Research Career Scientist (RCS) award. I fully concur with the committee's recommendation.
2. The RCS award will provide salary support for Dr. Chang's VA appointment for a five-year period beginning **October 1, 2019** and ending **September 30, 2024**.
3. A mid-term report is due on **March 1, 2022**. Funding beyond the RCS mid-term will be conditional on active Merit funding as a Principal Investigator; strong research productivity evidenced by publications in high impact journals; evidence of active collaborations especially with VA clinician investigators; mentoring and training of VA career development awardees; service at the local VA; and national service on VA Merit Review panels or other national advisory panels. The due date for submitting a renewal application will be **March 1, 2024**.
4. Dr. Chang is reminded to cite his VA affiliation and RCS award on all public reports and presentations during the award period, in accordance with the policies stated in VHA Handbook 1200.19 (dated July 10, 2014). For example, "Dr. Chang is the recipient of a Research Career Scientist award (#1IK6BX004835) from the Department of Veterans Affairs." Failure to acknowledge VA support or employment may, at the discretion of the Chief Research and Development Officer and the research Service Director, result in the revocation of the award.
5. If you have any questions regarding this memorandum, please contact Jane Battles, Ph.D., at jane.battles@va.gov or 202-443-5781.
6. Please convey my sincere congratulations to Dr. Chang.


Christopher T. Bever Jr., M.D., MBA

cc: Carl Grunfeld, M.D., Ph.D.
Jane Battles, Ph.D.
Sara Clark



College of Medicine
Interim Chairman

PO Box 100296
Gainesville, FL 32610-0296
352-273-9001
352-294-5712 Fax

March 16, 2022

Dear Sam,

Thank you for your submission of the CMN application entitled, "Next Generation ORS for Therapy of Childhood Diarrhea." The CMN Awards Committee reviewed your application for Bridge support. I'm please to inform you that your proposal was approved and will be funded.


This award specifically gives you 10% protected research time to revise your grants and resubmit those that have already been submitted. I look forward to seeing your success in this endeavor.

This award could not be made possible without the CMN funds and the student leaders who organize Dance Marathon. I am inspired by the effort and dedication of these students and the CMN community as a whole. As Mahatma Gandhi once said "The best way to find yourself is to lose yourself in the service of others." I am honored to work with the CMN team, the students and you in serving our patients, moving innovation forward, and educating the next generation of pediatricians and leaders.

If you have any questions, please contact Teresa Welch.

Thank you again for all that you do.

Sincerely,



Desmond Schatz MD
Professor and Interim Chair of Pediatrics



Recipient Information	Federal Award Information
1. Recipient Name UNIVERSITY OF FLORIDA 1523 UNION RD RM 207 GAINESVILLE, 32611	11. Award Number 1R21AI169282-01A1
2. Congressional District of Recipient 03	12. Unique Federal Award Identification Number (FAIN) R21AI169282
3. Payment System Identifier (ID) 1596002052A1	13. Statutory Authority 42 USC 241 42 CFR 52
4. Employer Identification Number (EIN) 596002052	14. Federal Award Project Title Next generation ORS: Randomized controlled trial comparing ORS with calcium vs standard ORS in reducing severity of adults with acute watery diarrhea
5. Data Universal Numbering System (DUNS) 969663814	15. Assistance Listing Number 93.855
6. Recipient's Unique Entity Identifier NNFQH1JAPEP3	16. Assistance Listing Program Title Allergy and Infectious Diseases Research
7. Project Director or Principal Investigator Sam X Cheng, MD sam.cheng@ufl.edu 352-273-9358	17. Award Action Type New Competing
8. Authorized Official Stephanie Gray ufawards@ufl.edu 352-273-5135	18. Is the Award R&D? Yes
Federal Agency Information	Summary Federal Award Financial Information
9. Awarding Agency Contact Information SANA ISLAM Shaikh Grants Management Specialist NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	19. Budget Period Start Date 01/06/2023 – End Date 12/31/2023
10. Program Official Contact Information Amir E Zeituni NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES amir.zeituni@nih.gov 301-496-2550	20. Total Amount of Federal Funds Obligated by this Action 20 a. Direct Cost Amount \$285,351 20 b. Indirect Cost Amount \$214,357 \$70,994
	21. Authorized Carryover
	22. Offset
	23. Total Amount of Federal Funds Obligated this budget period \$285,351
	24. Total Approved Cost Sharing or Matching, where applicable \$0
	25. Total Federal and Non-Federal Approved this Budget Period \$285,351
	26. Project Period Start Date 01/06/2023 – End Date 12/31/2024
	27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period \$285,351
	28. Authorized Treatment of Program Income Additional Costs
	29. Grants Management Officer - Signature Jason A. Lundgren
30. Remarks Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.	



EXPLORATORY/DEVELOPMENT GRANT
Department of Health and Human Services
National Institutes of Health

Notice of Award



NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

SECTION I – AWARD DATA – 1R21AI169282-01A1

Principal Investigator(s):

Sam X Cheng, MD

Award e-mailed to: nihawards@research.ufl.edu

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$285,351 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to UNIVERSITY OF FLORIDA in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R21AI169282. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Jason A. Lundgren
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)

Federal Direct Costs	\$214,357
Federal F&A Costs	\$70,994
Approved Budget	\$285,351
Total Amount of Federal Funds Authorized (Federal Share)	\$285,351
TOTAL FEDERAL AWARD AMOUNT	\$285,351
AMOUNT OF THIS ACTION (FEDERAL SHARE)	\$285,351

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$285,351	\$285,351
2	\$104,632	\$104,632

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

Payment System Identifier: 1596002052A1
Document Number: RAI169282A
PMS Account Type: P (Subaccount)
Fiscal Year: 2023

IC	CAN	2023	2024
AI	8472364	\$285,351	\$104,632

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: M64B B / **OC:** 41021 / **Released:** Lundgren, Jason 12/23/2022
Award Processed: 01/06/2023 12:09:32 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 1R21AI169282-01A1

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – STANDARD TERMS AND CONDITIONS – 1R21AI169282-01A1

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 75.
- National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.

f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of “Research and Development” at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase VII Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R21AI169282. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of [Public Law 110-85](#)), the “responsible party” must register “applicable clinical trials” on the [ClinicalTrials.gov Protocol Registration System Information Website](#). NIH encourages registration of all trials whether required under the law or not. For more information, see http://grants.nih.gov/ClinicalTrials_fdaaa/

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:

SECTION IV – AI SPECIFIC AWARD CONDITIONS – 1R21AI169282-01A1

Clinical Trial Indicator: Yes

This award supports one or more NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

The budget period anniversary start date for future year(s) will be January 1.

This is a Modular Award without direct cost categorical breakdowns in accordance with the guidelines published in the NIH Grants Policy Statement, see https://grants.nih.gov/grants/policy/nihgps/HTML5/section_13/13.5_post-award_administration.htm.

Recipients are required to allocate and account for costs related to this award by category within their institutional accounting system in accordance with applicable cost principles.

This Notice of Award (NoA) includes funds for **INTL CENTRE FOR DIARRHOEAL DISEASE RES, BANGLADESH.**

This Notice of Award (NoA) includes funds for **University of Kentucky.**

Research conducted at the following site(s) must be reported in the Research Performance Progress Report (RPPR), Section G.9 (Foreign component):

INTL CENTRE FOR DIARRHOEAL DISEASE RES, BANGLADESH

This award includes human subject research studies and must conform to the DHHS policies for the [Protection of Human Subjects](#) research, which are a term and condition of award. Human subjects research is covered by the 2018 Common Rule, and may not be initiated until the associated protocols have received IRB approval as specified in [45 CFR 46](#). Failure to comply with the terms and conditions of award may result in the disallowance of costs and/or additional enforcement actions as outlined in Section 8.5 of the NIH Grants Policy Statement.

This award is subject to the NIAID Clinical Terms of Award incorporated by reference, and can be accessed via the following World Wide Web address: <https://www.niaid.nih.gov/grants-contracts/niaid-clinical-terms-award> All submissions required by the NIAID Clinical Terms of Award must be forwarded electronically to the NIAID Program Official identified on this Notice of Award.

1. The clinical trial(s) supported by this award are subject to the plan dated 03/16/2022 from the competing application which adheres to the NIH policy on *Dissemination of NIH-Funded Clinical Trial Information*. As noted, the clinical trial(s) funded by this award will be registered in ClinicalTrials.gov not later than 21 calendar days after enrollment of the first participant and primary summary results reported in ClinicalTrials.gov, not later than one year after the completion date. The reporting of summary results is required by this term of award even if the primary completion date occurs after the period of performance.
2. This award is subject to additional certification requirements with each submission of the Annual, Interim, and Final Research Performance Progress Report (RPPR). The recipient must agree to the following annual certification when submitting each RPPR. By submitting the RPPR, the AOR signifies compliance, as follows:

In submitting the RPPR, the SO (or PD/PI with delegated authority), certifies to the best of his/her knowledge that, for all clinical trials funded under this NIH award, the recipient and all investigators conducting NIH-funded clinical trials are

in compliance with the recipient's plan addressing compliance with the NIH Policy on Dissemination of NIH-Funded Clinical Trial Information. Any clinical trial funded in whole or in part under this award has been registered in ClinicalTrials.gov or will be registered not later than 21 calendar days after enrollment of the first participant. Summary results have been submitted to ClinicalTrials.gov or will be submitted not later than one year after the completion date, even if the completion date occurs after the period of performance.

Highly Pathogenic Agents:

NIAID defines a Highly Pathogenic Agent as an infectious Agent or Toxin that may warrant a biocontainment safety level of BSL3 or higher according to the current edition of the CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL) (<https://www.cdc.gov/labs/BMBL.html>). Research funded under this grant must adhere to the BMBL, including using the BMBL-recommended biocontainment level at a minimum. If the Institutional Biosafety Committee (IBC) (or equivalent body) or designated institutional biosafety official recommends a higher biocontainment level, the higher recommended containment level must be used.

When submitting future Progress Reports indicate at the beginning of the report:

If no research with a Select Agent (see 42 CFR 73 for the relevant human Select Agents and Toxins; and 7 CFR 331 and 9 CFR 121 for the relevant animal and plant Select Agents and Toxins at <https://www.selectagents.gov/regulations/> and <https://www.selectagents.gov/sat/list.htm>) and/or has been performed or is planned to be performed under this grant.

If the IBC or equivalent body or official has determined, for example, by conducting a risk assessment, that the work being planned or performed under this grant may be conducted at a biocontainment safety level that is lower than BSL3.

If the work involves Select Agents and/or Highly Pathogenic Agents, also address the following points:

Any NIAID pre-approved changes in the use of the Select Agents and/or Highly Pathogenic Agents including its restricted experiments that have resulted in a change in the required biocontainment level, and any resultant change in location, if applicable, as determined by the IBC or equivalent body or official.

If work with a new or additional Select Agents and/or Highly Pathogenic Agents is proposed in the upcoming project period, provide:

- A list of the new and/or additional Agent(s) that will be studied;
- A description of the work that will be done with the Agent(s), and whether or not the work is a restricted experiment;
- The title and location for each biocontainment resource/facility, including the name of the organization that operates the facility, and the biocontainment level at which the work will be conducted, with documentation of approval by the IBC or equivalent body or official. It is important to note if the work is being done in a new location;
- Any biosafety incidents that occurred and were reported to NIH/NIAID.

SPREADSHEET SUMMARY

AWARD NUMBER: 1R21AI169282-01A1

INSTITUTION: UNIVERSITY OF FLORIDA

Budget	Year 1	Year 2
TOTAL FEDERAL DC	\$214,357	\$83,957
TOTAL FEDERAL F&A	\$70,994	\$20,675
TOTAL COST	\$285,351	\$104,632

Facilities and Administrative Costs	Year 1	Year 2
F&A Cost Rate 1	52.5%	52.5%
F&A Cost Base 1	\$135,226	\$39,381
F&A Costs 1	\$70,994	\$20,675



EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

Grant Number: 1R41HD092133-01
FAIN: R41HD092133

Principal Investigator(s):
Sam X Cheng, MD

Project Title: Development of CaSR nutrient therapy for childhood diarrhea

Dr. Wagner, Richard
Medosome Biotech, LLC
12085 Research Drive
Alachua, FL 326156832

Award e-mailed to: rewagner@mdbiotec.com

Period Of Performance:

Budget Period: 04/01/2017 – 03/31/2018

Project Period: 04/01/2017 – 03/31/2018

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$223,899 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to MEDOSOME BIOTEC, LLC in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 15 USC 638 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number R41HD092133. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Cammie T La
Grants Management Officer
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN
DEVELOPMENT

Additional information follows

SECTION I – AWARD DATA – 1R41HD092133-01**Award Calculation (U.S. Dollars)**

Salaries and Wages	\$22,250
Personnel Costs (Subtotal)	\$22,250
Consultant Services	\$1,000
Materials & Supplies	\$21,286
Other	\$7,500
Subawards/Consortium/Contractual Costs	\$135,001
Publication Costs	\$1,000

Federal Direct Costs	\$188,037
Federal F&A Costs	\$21,214
Approved Budget	\$209,251
Fee	\$14,648
Total Amount of Federal Funds Obligated (Federal Share)	\$223,899
TOTAL FEDERAL AWARD AMOUNT	\$223,899

AMOUNT OF THIS ACTION (FEDERAL SHARE) **\$223,899**

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$223,899	\$223,899

Fiscal Information:

CFDA Name: Child Health and Human Development Extramural Research
CFDA Number: 93.865
EIN: 1471234379A1
Document Number: RHD092133A
PMS Account Type: P (Subaccount)
Fiscal Year: 2017

IC	CAN	2017
HD	8014704	\$223,899

NIH Administrative Data:

PCC: PGNB -GG / **OC:** 414A / **Released:** LAC 03/17/2017

Award Processed: 03/23/2017 12:13:34 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 1R41HD092133-01

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 1R41HD092133-01

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 75.
- National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.

f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

This award is subject to the life cycle certification requirements set forth in Section 18.5.5.5 of the NIH Grants Policy Statement. Awardees are not required to submit this certification directly to NIH but must instead complete the certification, maintain it on file in accordance with the records and retention policy in Section 8.4.2 of the NIH Grants Policy Statement, and make these certifications available to Federal officials upon request.

A certification is required at the following times:

- For STTR Phase I Awardees: At the time of receiving final payment or disbursement from the Payment Management System.
- For STTR Phase II Awardees: Prior to receiving more than 50% of the total award amount and prior to final payment or disbursement from the Payment Management System.

If the grantee cannot complete this certification or cannot ensure compliance with the certification process, it should notify the GMO immediately. If resolution cannot be reached, the GMO will void or terminate the grant, as appropriate.

The certification form is available in fillable format at: <http://grants.nih.gov/grants/forms.htm#sbir>.

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R41HD092133. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award represents the final year of the competitive segment for this grant. See the NIH Grants Policy Statement Section 8.6 Closeout for complete closeout requirements at: <http://grants.nih.gov/grants/policy/policy.htm#gps>.

A final expenditure Federal Financial Report (FFR) (SF 425) must be submitted through the eRA Commons (Commons) within 120 days of the expiration date; see the NIH Grants Policy Statement Section 8.6.1 Financial Reports, <http://grants.nih.gov/grants/policy/policy.htm#gps>, for additional information on this submission requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no discrepancies between the final FFR expenditure data and the Payment Management System's (PMS) quarterly cash transaction data. A final quarterly federal cash transaction report is not required for awards in PMS B subaccounts (i.e., awards to foreign entities and to Federal agencies). NIH will close the awards using the last recorded cash drawdown level in PMS for awards that do not require a final FFR on expenditures or quarterly federal cash transaction reporting. It is important to note that for financial closeout, if a grantee fails to submit a required final expenditure FFR, NIH will close the grant using the last recorded cash drawdown level. If the grantee submits a final expenditure FFR but does not reconcile any discrepancies between expenditures reported on the final expenditure FFR and the last cash report to PMS, NIH will close the award at the lower amount. This could be considered a debt or result in disallowed costs.

A Final Invention Statement and Certification form (HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted within 120 days of the expiration date. The HHS 568 form may be downloaded at: <http://grants.nih.gov/grants/forms.htm>. This paragraph does not apply to Training grants, Fellowships, and certain other programs—i.e., activity codes C06, R13, R25, S10.

Unless an application for competitive renewal is submitted, a final progress report must also be submitted within 120 days of the expiration date. Instructions for preparing a SBIR/STTR Phase II Final Progress Report are at: http://grants.nih.gov/grants/funding/finalprogressreport_SBIR_PhaseII.doc. All 15 items, plus requested attachments, should be provided. If uploaded through the Commons all documents must be combined into a single pdf. Any other specific requirements set forth in the terms and conditions of the award must also be addressed in the final progress report. Institute/Centers may accept the progress report contained in competitive renewal (type 2) in lieu of a separate final progress report. Contact the awarding IC for IC-specific policy regarding acceptance of a progress report contained in a competitive renewal application in lieu of a separate final progress report.

NIH strongly encourages electronic submission of the final progress report and the final invention statement through the Closeout feature in the Commons, but will accept an email or hard copy submission as indicated below.

Email: The final progress report and final invention statement may be e-mailed as PDF attachments to: NIHCloseoutCenter@mail.nih.gov.

Hard copy: Paper submissions of the final progress report and the final invention statement may be faxed to the NIH Division of Central Grants Processing, Grants Closeout Center, at 301-480-2304, or mailed to:

National Institutes of Health
Office of Extramural Research
Division of Central Grants Processing
Grants Closeout Center
6705 Rockledge Drive
Suite 5016, MSC 7986
Bethesda, MD 20892-7986 (for regular or U.S. Postal Service Express mail)
Bethesda, MD 20817 (for other courier/express deliveries only)

NOTE: If this is the final year of a competitive segment due to the transfer of the grant to another institution, then a Final Progress Report is not required. However, a final expenditure FFR is required and should be submitted electronically as noted above. If not already submitted, the Final Invention Statement is required and should be sent directly to the assigned Grants Management Specialist.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:

Additional Costs

SECTION IV – HD Special Terms and Conditions – 1R41HD092133-01

Intellectual property rights: Normally, the awardee organization retains the principal worldwide patent rights to any invention developed with United States Government support. Under Title 37 Code of Federal Regulations Part 401, the Government receives a royalty-free license for its use, reserves the right to require the patent holder to license others in certain circumstances, and requires that anyone exclusively licensed to sell the invention in the United States must normally manufacture it substantially in the United States.

Rights and obligations related to inventions created or reduced to practice as a result of this award are detailed in 35 U.S.C. 205 and 37 CFR Part 401. These inventions must be reported to the Extramural Invention Reporting and Technology Resources Branch, OPERA, NIH, 6701 Rockledge Drive, MSC 7750, Bethesda, MD 20892-7750, (301) 435-1986. For additional information, access the NIH link on the Interagency Edison web site (www.iedison.gov) which includes an electronic invention statement reporting system, reference information and the text to 37 CFR 401.

To the extent authorized by 35 U.S.C., Section 205, the Government will not make public any information disclosing an NIH-supported invention for a 4-year period to allow the awardee organization a reasonable time to file a patent application, nor will the Government release any information that is part of that patent application

If applicable, the fee provided as part of this Notice of Award is in addition to direct and facilities and administrative costs. The fee is to be drawn down from the HHS Payment Management System in increments proportionate to the draw down of costs.

Allowable costs conducted by for-profit organizations will be determined by applying the cost principles of Contracts with Commercial Organizations set forth in 48 CFR, Subpart 31.2.

PAYMENT INFORMATION: A drawdown of funds may be made at any time; however, requests for advance funding must be timed to coincide with the organization's immediate cash needs, thus keeping to a minimum the amount of Federal cash held in recipient bank accounts.

To access award funds, recipients are required to provide financial information to the HHS Payment Management System (PMS). PMS is responsible for coordinating requests for funds, manners of payment, and associated reporting requirements. To setup your PMS access, complete a SF-1199A and the PMS Access Form, available at https://www.dpm.psc.gov/grant_recipient/access_procedure/access_procedure.aspx?explorer.enabled=true and submit to your PMS Account Liaison.

Recipients previously receiving funding through the PMS should contact their PMS Account Liaison for additional information.

A listing of PMS Account Liaison's is available at https://www.dpm.psc.gov/contacts/dpm_contact_list/univ_nonprofit.aspx.

This award includes funds awarded for consortium activity with University of Florida.

Consortia are to be established and administered as described in the NIH Grants Policy Statement (rev. 11/16) (<http://grants.nih.gov/grants/policy/nihgps/nihgps.pdf>).

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Melinda Bixby
Email: mindy.bixby@nih.gov **Phone:** (301) 402-3204 **Fax:** (301) 496-3791

Program Official: Gilman D. Grave
Email: graveg@mail.nih.gov **Phone:** (301) 496-5593 **Fax:** (301) 480-9791

SPREADSHEET SUMMARY

GRANT NUMBER: 1R41HD092133-01

INSTITUTION: MEDOSOME BIOTEC, LLC

Budget	Year 1
Salaries and Wages	\$22,250
Personnel Costs (Subtotal)	\$22,250
Consultant Services	\$1,000
Materials & Supplies	\$21,286
Other	\$7,500
Subawards/Consortium/Contractual Costs	\$135,001
Publication Costs	\$1,000
FEE	\$14,648
TOTAL FEDERAL DC	\$188,037
TOTAL FEDERAL F&A	\$21,214
TOTAL COST	\$223,899

Facilities and Administrative Costs	Year 1
F&A Cost Rate 1	40%
F&A Cost Base 1	\$53,036
F&A Costs 1	\$21,214

PI Φ CHENG S	COPI
Coll (29) MEDICINE	Coll
Dept (PED) PEDIATRICS	Dept

Title CALCIUM RECEPTOR ACTION IN CHILDHOOD DIARRHEA

Sponsor (F027) NATL INST OF HLTH	Award Action New
Division (12) NICHD - CHLD HLTH & HUMAN DEV	Category Φ Research - Basic
Sponsor # K08 HD079674 GM02452	Award Type Grant
Prime Agency	Terms FDP & Federal Grant Research Terms & Conditions
Prime Agency #	Special Program
Subrecipient Φ	Rebudgeting Control (KK) Level Φ 3
Status	<input type="checkbox"/> Award Prohibits Indirect Costs - Not Subject to CAS <input type="checkbox"/> Carryforward Requires Prior Approval <input type="checkbox"/> Interest Earned - C&G Reporting Required <input type="checkbox"/> Financial Conflict of Interest Management Plan Φ <input type="checkbox"/> Technology Control Plan (TCP) Φ <input type="checkbox"/> Clinical Trial
CFDA 93.865	
CSFA	
SOF G000010	
DEPTID 29091000	

Periods	Begin Date	End Date	Subjects	Status	Approval #	Expiration
Budget Period	04/10/2014	03/31/2015	IRB - Human Φ	None		
Project Period	04/10/2014	03/31/2019	IACUC - Animal Φ	Approved	201207567	09/20/2014

Award Information		Current Project Funding		Cumulative Funding	
Contract #	00089970	Direct Amount	112,825.00	Project Funding (includes any carry over)	121,851.00
Project #	00109224	Indirect Amount	9,026.00	Project Awarded Amount	121,851.00
Indirect Rate	8.0%	Total Award	121,851.00	Mandatory Cost Share	
Indirect Base	MTDC	Mandatory Cost Share		Voluntary Committed Cost Share	
		Voluntary Committed Cost Share			

Remarks

Department NOA Contact	PEDIATRICS	Name	BRIAN C. MILLER	UF Authorized Signature
DSR Processor	JAJ	DSR Reviewer	VT	Title
			ASSISTANT DIRECTOR OF RESEARCH	

E:2 W:0 I:7 Distribution: DSR, C&G Accounting, Department NOA Contact, Principal Investigator

Teel, Vera D

From: era-notify@mail.nih.gov
Sent: Wednesday, April 09, 2014 12:33 AM
To: UF-Awards
Subject: NoA: 1 K08 HD079674-01 PI: Cheng, Sam
Attachments: temp377959418689859091.pdf

Grant Number: 1 K08 HD079674-01
Principal Investigator: Cheng, Sam X
Project Title: Calcium Receptor Action in Childhood Diarrhea
Institution: UNIVERSITY OF FLORIDA
CFDA: 93.865
OC: 415L
PCC: PGNB -KW
Award Issue Date: 04/09/2014
Grants Management Officer: Shaw-Cortez, Monica
Program Official: WINER, KAREN
Grants Specialist: Shaw-Cortez, Monica

13061111
①

*** This is an automated notification - Please do not reply to this message. ***



CLINICAL INVESTIGATOR AWARD
Department of Health and Human Services
National Institutes of Health

Notice of Award

Issue Date: 04/09/2014



EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

Grant Number: 1K08HD079674-01
FAIN: K08HD079674

Principal Investigator(s):
Sam X Cheng, MD

Project Title: Calcium Receptor Action in Childhood Diarrhea

Mr Prindle, Brian
Associate Director
219 Grinter Hall
PO Box 115500
Gainesville, FL 326115500

Award e-mailed to: ufawards@ufl.edu

Budget Period: 04/10/2014 – 03/31/2015
Project Period: 04/10/2014 – 03/31/2019

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$121,851 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to UNIVERSITY OF FLORIDA in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number K08HD079674. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with 42 CFR Part 50 Subpart F. Subsequent to the compliance date of the 2011 revised FCOI regulation (i.e., on or before August 24, 2012), Awardees must be in compliance with all aspects of the 2011 revised regulation; until then, Awardees must comply with the 1995 regulation. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Monica G. Shaw-Cortez
Grants Management Officer
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN
DEVELOPMENT

Additional information follows

SECTION I – AWARD DATA – 1K08HD079674-01**Award Calculation (U.S. Dollars)**

Salaries and Wages	\$75,000
Fringe Benefits	\$12,825
Other Costs	\$25,000

Federal Direct Costs	\$112,825
Federal F&A Costs	\$9,026
Approved Budget	\$121,851
Federal Share	\$121,851
TOTAL FEDERAL AWARD AMOUNT	\$121,851

AMOUNT OF THIS ACTION (FEDERAL SHARE)	\$121,851
--	------------------

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$121,851	\$121,851
2	\$121,851	\$121,851
3	\$121,851	\$121,851
4	\$121,851	\$121,851
5	\$121,851	\$121,851

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Number:	93.865
EIN:	1596002052A1
Document Number:	KHD079674A
PMS Account Type:	P (Subaccount)
Fiscal Year:	2014

IC	CAN	2014	2015	2016	2017	2018
HD	8014707	\$121,851	\$121,851	\$121,851	\$121,851	\$121,851

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: PGNB -KW / OC: 415L / Released: SHAWM 04/04/2014
Award Processed: 12/26/2013 10:57:56 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 1K08HD079674-01

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 1K08HD079674-01

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase V Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.



This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) K08HD079674. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

Treatment of Program Income:
Additional Costs

SECTION IV – HD Special Terms and Conditions – 1K08HD079674-01

This award includes funds for twelve months of support. The competing budget period is awarded for less than 12 months. Continuation awards will cycle on April 1. [NICHD is taking this action to redistribute start dates more evenly throughout the year.] Allowable preaward costs may be charged to this award, in accordance with institutional requirements for prior approval and the conditions outlined in the NIH Grants Policy Statement (rev. 10/13) (http://grants.nih.gov/grants/policy/nihgps_2013/nihgps_ch7.htm#selected_cost_items).



This award is subject to the requirements indicated in PA11-193, which are hereby incorporated by reference. Copies of this Funding Opportunity Announcement are available at <http://grants.nih.gov/grants/guide/index.html>.

A Mentor's Report is required for all NIH Mentored Career (K) Awards as part of the Continuation Progress Report. See Section 4.1.4.J of the PHS 2590 Instructions for more information (<http://grants.nih.gov/grants/funding/2590/phs2590.pdf>).

NIH requires the use of the eRA Research Performance Progress Report (RPPR) Module for the submission of all Streamlined Noncompeting Application Process (SNAP) and Fellowship progress reports with start dates on or after July 1, 2013. See NIH Guide Notice NOT-OD-13-035 (<http://grants.nih.gov/grants/guide/notice-files/NOT-OD-13-035.html>).

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Monica G. Shaw-cortez
Email: shawcm@mail.nih.gov **Phone:** 301-435-7002 **Fax:** 301-480-4783

Program Official: Karen Winer
Email: winerk@mail.nih.gov **Phone:** (301) 435-6877 **Fax:** (301) 480-9791

SPREADSHEET SUMMARY

GRANT NUMBER: 1K08HD079674-01

INSTITUTION: UNIVERSITY OF FLORIDA

Budget	Year 1	Year 2	Year 3	Year 4	Year 5
Salaries and Wages	\$75,000	\$75,000	\$75,000	\$75,000	\$75,000
Fringe Benefits	\$12,825	\$12,825	\$12,825	\$12,825	\$12,825
Other Costs	\$25,000	\$25,000	\$25,000	\$25,000	\$25,000
TOTAL FEDERAL DC	\$112,825	\$112,825	\$112,825	\$112,825	\$112,825
TOTAL FEDERAL F&A	\$9,026	\$9,026	\$9,026	\$9,026	\$9,026
TOTAL COST	\$121,851	\$121,851	\$121,851	\$121,851	\$121,851

Facilities and Administrative Costs	Year 1	Year 2	Year 3	Year 4	Year 5
F&A Cost Rate 1	8%	8%	8%	8%	8%
F&A Cost Base 1	\$112,825	\$112,825	\$112,825	\$112,825	\$112,825
F&A Costs 1	\$9,026	\$9,026	\$9,026	\$9,026	\$9,026

Budget Justification

Personnel:

Sam Cheng, MD/PhD (Principal Investigator, 9.0 calendar effort). Dr. Cheng will be responsible for the design and conduct of this mentored research project and career development award. He will also be responsible for dissemination of the results via publications and presentations.

✓ **Mansour Mohamadzadeh, PhD** (Mentor, non measurable effort). Dr. Mohamadzadeh will have the responsibility of guiding and assisting Dr. Cheng in the conduct of the proposed experiments as well as professional development. He will be responsible for meeting with him every week to discuss the progress of his research and guide his development as an independent investigator. He will chair a research oversight committee meeting every 6 months and will be responsible for Dr. Cheng's annual evaluation report.

Stephanie Karst, PhD (Mentoring committee member, non-measurable effort). Together with Dr. Mohamadzadeh, Dr. Karst will have the responsibility of guiding Dr. Cheng in the conduct of the in vivo diarrhea studies (AIM 3) of his mentored award, in particular the murine models of Norovirus diarrhea.

✓ **Qing Zhang, MD/PhD** (Mentoring committee member, non-measurable effort). Dr. Zhang will provide advice and guidance on proposed gut motility studies.

Christopher Jolley, MD: (Mentoring committee member, non measurable effort). Dr. Jolley will meet with Dr. Cheng twice a year as part of his mentoring committee meetings and will provide guidance during his career development.

✓ **Scott Rivkees, MD:** (Mentoring committee member, non-measurable effort). Dr. Rivkees will meet with Dr. Cheng every week in joint weekly lab meeting, every month as his program Chair and twice a year as a member of her mentoring committee. He will also provide career guidance and will help ensure that Dr. Cheng is on track in his timeline to become an independent investigator.

Supplies:

Animals: Animal purchase, breeding and housing funds are required to complete the studies proposed in this application. There are 2 species and 5 colonies which will meet the experimental goals of this project. The 2 species are: Sprague-Dawley rats and C57BL/6 mice. The 5 mouse colonies are: 1) Villin-Cre/Floxed CaSR mice (gut epithelium CaSR conditional knockout mice), 2) Nestin-Cre/Floxed CaSR mice (gut neuron CaSR conditional knockout mice), and 3) Villin-Cre mice (control), 4) Nestin-Cre mice (control), and 5) Floxed CaSR mice (control). The CaSR knockout and control mice are bred by the PI's lab whereas Sprague-Dawley rats and C57BL/6 mice will be purchased from Taconic or Charles River. All animals will be maintained and housed at the Communicore Animal Facility of College of Medicine, University of Florida. To purchase the required number of animals, it will cost \$3,214/year [4 cages at \$160.70 (including ordering and shipping) every 2 weeks for 40 weeks per year]. To breed and generate the required number of knockout animals, it will cost \$13,870/year (averaged 40 cages per day at \$0.95 per cage per day for 365 days). Total costs for animal per year are \$17,000/year x 5 years.

Specially modified animal diets: A control diet and 3 CaSR agonist-enriched diets are required for studies proposed in Aims 1-3 in order to nutritionally activate the intestinal CaSR and will be purchased from Harlan. Total cost for these diets will be about \$1000/year.

Pharmaceuticals: Examples of pharmaceuticals needed for aims 1 and 2 include R-568, NPS 2143, Isoflurane. The studies proposed in Aim3 will also use AMG 641. Total cost for these agents will be about \$1000/year.

Chemicals/reagents: Chemicals and reagents needed in this proposal will cost \$2000/year for years 1-3, and \$1000 in years 4 and 5.

Toxins: Tetrodotoxin, Cholera toxin, STa, NSP4 and TTX are required to complete the studies proposed in this application. They will cost \$1000/year for years 1-3, and \$2000/year in years 4 and 5.

Disposables: Disposables such as pipette tips, storage boxes, 96-well plates, eppendorf tubes and fixative containers are required to cover bench supply costs. Total costs for disposables will be \$1,000 per year.

Travel: A travel expense will be used to support attendance at annual conferences such as American Gastroenterology Society, Pediatric Academic Society, and North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition. Data from this project will be presented at the meetings attended. Total travel costs will be \$2000 per year.

Equipment: There are no equipment costs associated with this application as the PI and mentors have all the necessary tools already available for the PI's use.

RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 1

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2014

* End Date: 03-31-2015

Budget Period: 1

A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requ Salar
1.	Dr.	Sam	Xianjun	Cheng	M.D.	PD/PI	175,000.00	9		75,
Total Funds Requested for all Senior Key Persons in the attached file										
Additional Senior Key Persons:				File Name:		Mime Type:				Total

B. Other Personnel

* Number of Personnel	* Project Role	Cal. Months	Acad. Months	Sum. Months	* Req Sala
Total Number Other Personnel					
Total Salary, Wages and					

RESEARCH & RELATED Budget (A-B) (Funds Requested)

Tracking Number:

RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 1

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2014

* End Date: 03-31-2015

Budget Period: 1

C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

D. Travel

Funds Requested (\$)

1. Domestic Travel Costs (Incl. Canada, Mexico, and U.S. Possessions)

2. Foreign Travel Costs

Total Travel Cost

E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance

2. Stipends

3. Travel

4. Subsistence

5. Other:

Number of Participants/Trainees

Total Participant/Trainee Support Costs

0.00

RESEARCH & RELATED Budget {C-E} (Funds Requested)

RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 1

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2014

* End Date: 03-31-2015

Budget Period: 1

F. Other Direct Costs		Funds Requested (\$)
1. Materials and Supplies		25,000.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
8. Tuition		0.00
9. Other		0.00
Total Other Direct Costs		25,000.00

G. Direct Costs	Funds Requested (\$)
Total Direct Costs (A thru F)	112,825.00

H. Indirect Costs				
Indirect Cost Type		Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1. a. Sponsored Research On Campus		8	112,825.00	9,026.00
			Total Indirect Costs	9,026.00
Cognizant Federal Agency		DHHS, Darryl Mayes, 301-492-4855		
(Agency Name, POC Name, and POC Phone Number)				

I. Total Direct and Indirect Costs	Funds Requested (\$)
Total Direct and Indirect Institutional Costs (G + H)	121,851.00

J. Fee	Funds Requested (\$)

K. * Budget Justification	File Name: Budget_Justification1003342989.pdf	Mime Type: application/pdf
	(Only attach one file.)	

RESEARCH & RELATED Budget {F-K} (Funds Requested)

RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 2

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2015

* End Date: 03-31-2016

Budget Period: 2

A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requ Salar
1.	Dr.	Sam	Xianjun	Cheng	M.D.	PD/PI	175,000.00	9		75,
Total Funds Requested for all Senior Key Persons in the attached file										
Additional Senior Key Persons:				File Name:		Mime Type:				Tot

B. Other Personnel

* Number of Personnel	* Project Role	Cal. Months	Acad. Months	Sum. Months	* Req Sala
Total Number Other Personnel					
					Total Salary, Wages and

RESEARCH & RELATED Budget (A-B) (Funds Requested)

Tracking Number:

RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 2

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2015

* End Date: 03-31-2016

Budget Period: 2

C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

D. Travel

Funds Requested (\$)

1. Domestic Travel Costs (Incl. Canada, Mexico, and U.S. Possessions)

2. Foreign Travel Costs

Total Travel Cost

E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance

2. Stipends

3. Travel

4. Subsistence

5. Other:

Number of Participants/Trainees

Total Participant/Trainee Support Costs

0.00

RESEARCH & RELATED Budget {C-E} (Funds Requested)

RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 2

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2015

* End Date: 03-31-2016

Budget Period: 2

F. Other Direct Costs		Funds Requested (\$)
1. Materials and Supplies		25,000.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
8. Tuition		0.00
9. Other		0.00
Total Other Direct Costs		25,000.00

G. Direct Costs	Funds Requested (\$)
Total Direct Costs (A thru F)	112,825.00

H. Indirect Costs				
	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1. a.	Sponsored Research On Campus	8	112,825.00	9,026.00
			Total Indirect Costs	9,026.00
Cognizant Federal Agency		DHHS, Darryl Mayes, 301-492-4855		
(Agency Name, POC Name, and POC Phone Number)				

I. Total Direct and Indirect Costs	Funds Requested (\$)
Total Direct and Indirect Institutional Costs (G + H)	121,851.00

J. Fee	Funds Requested (\$)
--------	----------------------

K. * Budget Justification	File Name: Budget_Justification1003342989.pdf	Mime Type: application/pdf
(Only attach one file.)		

RESEARCH & RELATED Budget {F-K} (Funds Requested)

RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 3

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2016

* End Date: 03-31-2017

Budget Period: 3

A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Reque Salar
1.	Dr.	Sam	Xianjun	Cheng	M.D.	PD/PI	175,000.00	9		75,
Total Funds Requested for all Senior Key Persons in the attached file										
Additional Senior Key Persons:				File Name:		Mime Type:				Tot

B. Other Personnel

* Number of Personnel	* Project Role	Cal. Months	Acad. Months	Sum. Months	* Reque Sala
Total Number Other Personnel					
					Total Salary, Wages and

RESEARCH & RELATED Budget (A-B) (Funds Requested)

Tracking Number:

RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 3

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2016

* End Date: 03-31-2017

Budget Period: 3

C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

D. Travel

Funds Requested (\$)

1. Domestic Travel Costs (Incl. Canada, Mexico, and U.S. Possessions)

2. Foreign Travel Costs

Total Travel Cost

E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance

2. Stipends

3. Travel

4. Subsistence

5. Other:

Number of Participants/Trainees

Total Participant/Trainee Support Costs

0.00

RESEARCH & RELATED Budget {C-E} (Funds Requested)

RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 3

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2016

* End Date: 03-31-2017

Budget Period: 3

F. Other Direct Costs		Funds Requested (\$)
1. Materials and Supplies		25,000.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
8. Tuition		0.00
9. Other		0.00
Total Other Direct Costs		25,000.00

G. Direct Costs	Funds Requested (\$)
Total Direct Costs (A thru F)	112,825.00

H. Indirect Costs				
Indirect Cost Type		Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1. a. Sponsored Research On Campus		8	112,825.00	9,026.00
			Total Indirect Costs	9,026.00
Cognizant Federal Agency		DHHS, Darryl Mayes, 301-492-4855		
(Agency Name, POC Name, and POC Phone Number)				

I. Total Direct and Indirect Costs	Funds Requested (\$)
Total Direct and Indirect Institutional Costs (G + H)	121,851.00

J. Fee	Funds Requested (\$)
--------	----------------------

K. * Budget Justification	File Name: Budget_Justification1003342989.pdf	Mime Type: application/pdf
(Only attach one file.)		

RESEARCH & RELATED Budget {F-K} (Funds Requested)

RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 4

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2017

* End Date: 03-31-2018

Budget Period: 4

A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requ Salar
1.	Dr.	Sam	Xianjun	Cheng	M.D.	PD/PI	175,000.00	9		75,
Total Funds Requested for all Senior Key Persons in the attached file										
Additional Senior Key Persons:				File Name:		Mime Type:				Tot

B. Other Personnel

* Number of Personnel	* Project Role	Cal. Months	Acad. Months	Sum. Months	* Req Sala
Total Number Other Personnel					
					Total Salary, Wages and

RESEARCH & RELATED Budget (A-B) (Funds Requested)

Tracking Number:

RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 4

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2017

* End Date: 03-31-2018

Budget Period: 4

C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

D. Travel

Funds Requested (\$)

1. Domestic Travel Costs (Incl. Canada, Mexico, and U.S. Possessions)

2. Foreign Travel Costs

Total Travel Cost

E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance

2. Stipends

3. Travel

4. Subsistence

5. Other:

Number of Participants/Trainees

Total Participant/Trainee Support Costs

0.00

RESEARCH & RELATED Budget {C-E} (Funds Requested)

RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 4

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2017

* End Date: 03-31-2018

Budget Period: 4

F. Other Direct Costs		Funds Requested (\$)
1. Materials and Supplies		25,000.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
8. Tuition		0.00
9. Other		0.00
Total Other Direct Costs		25,000.00

G. Direct Costs	Funds Requested (\$)
Total Direct Costs (A thru F)	112,825.00

H. Indirect Costs				
	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1. a.	Sponsored Research On Campus	8	112,825.00	9,026.00
Total Indirect Costs				9,026.00
Cognizant Federal Agency		DHHS, Darryl Mayes, 301-492-4855		
(Agency Name, POC Name, and POC Phone Number)				

I. Total Direct and Indirect Costs	Funds Requested (\$)
Total Direct and Indirect Institutional Costs (G + H)	121,851.00

J. Fee	Funds Requested (\$)
--------	----------------------

K. * Budget Justification	File Name: Budget_Justification1003342989.pdf	Mime Type: application/pdf
(Only attach one file.)		

RESEARCH & RELATED Budget (F-K) (Funds Requested)

RESEARCH & RELATED BUDGET - SECTION A & B, BUDGET PERIOD 5

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2018

* End Date: 03-31-2019

Budget Period: 5

A. Senior/Key Person

Prefix	* First Name	Middle Name	* Last Name	Suffix	* Project Role	Base Salary (\$)	Cal. Months	Acad. Months	Sum. Months	* Requ Salar
1.	Dr.	Sam	Xianjun	Cheng	M.D.	PD/PI	175,000.00	9		75,
Total Funds Requested for all Senior Key Persons in the attached file										
Additional Senior Key Persons:				File Name:		Mime Type:				Tot

B. Other Personnel

* Number of Personnel	* Project Role	Cal. Months	Acad. Months	Sum. Months	* Req Sala
Total Number Other Personnel					Total Salary, Wages and

RESEARCH & RELATED Budget (A-B) (Funds Requested)

Tracking Number:

RESEARCH & RELATED BUDGET - SECTION C, D, & E, BUDGET PERIOD 5

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2018

* End Date: 03-31-2019

Budget Period: 5

C. Equipment Description

List items and dollar amount for each item exceeding \$5,000

Equipment Item

* Funds Requested (\$)

Total funds requested for all equipment listed in the attached file

Total Equipment

Additional Equipment:

File Name:

Mime Type:

D. Travel

Funds Requested (\$)

1. Domestic Travel Costs (Incl. Canada, Mexico, and U.S. Possessions)

2. Foreign Travel Costs

Total Travel Cost

E. Participant/Trainee Support Costs

Funds Requested (\$)

1. Tuition/Fees/Health Insurance

2. Stipends

3. Travel

4. Subsistence

5. Other:

Number of Participants/Trainees

Total Participant/Trainee Support Costs

0.00

RESEARCH & RELATED Budget {C-E} (Funds Requested)

RESEARCH & RELATED BUDGET - SECTIONS F-K, BUDGET PERIOD 5

* ORGANIZATIONAL DUNS: 969663814

* Budget Type: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: University of Florida Board of Trustees

* Start Date: 04-01-2018

* End Date: 03-31-2019

Budget Period: 5

F. Other Direct Costs		Funds Requested (\$)
1. Materials and Supplies		25,000.00
2. Publication Costs		
3. Consultant Services		
4. ADP/Computer Services		
5. Subawards/Consortium/Contractual Costs		
6. Equipment or Facility Rental/User Fees		
7. Alterations and Renovations		
8. Tuition		0.00
9. Other		0.00
Total Other Direct Costs		25,000.00

G. Direct Costs	Funds Requested (\$)
Total Direct Costs (A thru F)	112,825.00

H. Indirect Costs				
	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1. a.	Sponsored Research On Campus	8	112,825.00	9,026.00
			Total Indirect Costs	9,026.00
Cognizant Federal Agency		DHHS, Darryl Mayes, 301-492-4855		
(Agency Name, POC Name, and POC Phone Number)				

I. Total Direct and Indirect Costs	Funds Requested (\$)
Total Direct and Indirect Institutional Costs (G + H)	121,851.00

J. Fee	Funds Requested (\$)
--------	----------------------

K. * Budget Justification	File Name: Budget_Justification1003342989.pdf	Mime Type: application/pdf
(Only attach one file.)		

RESEARCH & RELATED Budget {F-K} (Funds Requested)

RESEARCH & RELATED BUDGET - Cumulative Budget

	Totals (\$)
Section A, Senior/Key Person	439,125.00
Section B, Other Personnel	
Total Number Other Personnel	
Total Salary, Wages and Fringe Benefits (A+B)	439,125.00
Section C, Equipment	
Section D, Travel	
1. Domestic	
2. Foreign	
Section E, Participant/Trainee Support Costs	
1. Tuition/Fees/Health Insurance	
2. Stipends	
3. Travel	
4. Subsistence	
5. Other	
6. Number of Participants/Trainees	
Section F, Other Direct Costs	125,000.00
1. Materials and Supplies	125,000.00
2. Publication Costs	
3. Consultant Services	
4. ADP/Computer Services	
5. Subawards/Consortium/Contractual Costs	
6. Equipment or Facility Rental/User Fees	
7. Alterations and Renovations	
8. Other 1	
9. Other 2	
10. Other 3	
Section G, Direct Costs (A thru F)	564,125.00
Section H, Indirect Costs	45,130.00
Section I, Total Direct and Indirect Costs (G + H)	609,255.00
Section J, Fee	